10 results on '"Bader Gary D."'
Search Results
2. The multimodality cell segmentation challenge: toward universal solutions
- Author
-
Ma, Jun, Xie, Ronald, Ayyadhury, Shamini, Ge, Cheng, Gupta, Anubha, Gupta, Ritu, Gu, Song, Zhang, Yao, Lee, Gihun, Kim, Joonkee, Lou, Wei, Li, Haofeng, Upschulte, Eric, Dickscheid, Timo, de Almeida, José Guilherme, Wang, Yixin, Han, Lin, Yang, Xin, Labagnara, Marco, Gligorovski, Vojislav, Scheder, Maxime, Rahi, Sahand Jamal, Kempster, Carly, Pollitt, Alice, Espinosa, Leon, Mignot, Tâm, Middeke, Jan Moritz, Eckardt, Jan-Niklas, Li, Wangkai, Li, Zhaoyang, Cai, Xiaochen, Bai, Bizhe, Greenwald, Noah F., Van Valen, David, Weisbart, Erin, Cimini, Beth A., Cheung, Trevor, Brück, Oscar, Bader, Gary D., and Wang, Bo
- Published
- 2024
- Full Text
- View/download PDF
3. Fatecode enables cell fate regulator prediction using classification-supervised autoencoder perturbation
- Author
-
Sadria, Mehrshad, Layton, Anita, Goyal, Sidhartha, and Bader, Gary D.
- Published
- 2024
- Full Text
- View/download PDF
4. Single-cell, single-nucleus, and spatial transcriptomics characterization of the immunological landscape in the healthy and PSC human liver
- Author
-
Andrews, Tallulah S., Nakib, Diana, Perciani, Catia T., Ma, Xue Zhong, Liu, Lewis, Winter, Erin, Camat, Damra, Chung, Sai W., Lumanto, Patricia, Manuel, Justin, Mangroo, Shantel, Hansen, Bettina, Arpinder, Bal, Thoeni, Cornelia, Sayed, Blayne, Feld, Jordan, Gehring, Adam, Gulamhusein, Aliya, Hirschfield, Gideon M., Ricciuto, Amanda, Bader, Gary D., McGilvray, Ian D., and MacParland, Sonya
- Published
- 2024
- Full Text
- View/download PDF
5. Drugst.One — a plug-and-play solution for online systems medicine and network-based drug repurposing
- Author
-
Maier, Andreas, primary, Hartung, Michael, additional, Abovsky, Mark, additional, Adamowicz, Klaudia, additional, Bader, Gary D, additional, Baier, Sylvie, additional, Blumenthal, David B, additional, Chen, Jing, additional, Elkjaer, Maria L, additional, Garcia-Hernandez, Carlos, additional, Helmy, Mohamed, additional, Hoffmann, Markus, additional, Jurisica, Igor, additional, Kotlyar, Max, additional, Lazareva, Olga, additional, Levi, Hagai, additional, List, Markus, additional, Lobentanzer, Sebastian, additional, Loscalzo, Joseph, additional, Malod-Dognin, Noel, additional, Manz, Quirin, additional, Matschinske, Julian, additional, Mee, Miles, additional, Oubounyt, Mhaned, additional, Pastrello, Chiara, additional, Pico, Alexander R, additional, Pillich, Rudolf T, additional, Poschenrieder, Julian M, additional, Pratt, Dexter, additional, Pržulj, Nataša, additional, Sadegh, Sepideh, additional, Saez-Rodriguez, Julio, additional, Sarkar, Suryadipto, additional, Shaked, Gideon, additional, Shamir, Ron, additional, Trummer, Nico, additional, Turhan, Ugur, additional, Wang, Rui-Sheng, additional, Zolotareva, Olga, additional, and Baumbach, Jan, additional
- Published
- 2024
- Full Text
- View/download PDF
6. PRMT5 is required for full-lengthHTTexpression by repressing multiple proximal intronic polyadenylation sites
- Author
-
AlQazzaz, Mona A., primary, Ciamponi, Felipe E., additional, Ho, Jolene C., additional, Maron, Maxim I., additional, Yadav, Manisha, additional, Sababi, Aiden M., additional, MacLeod, Graham, additional, Ahmadi, Moloud, additional, Bullivant, Garrett, additional, Tano, Vincent, additional, Langley, Sarah R., additional, Sánchez-Osuna, María, additional, Sachamitr, Patty, additional, Kushida, Michelle, additional, Richards, Laura, additional, Bardile, Costanza Ferrari, additional, Pouladi, Mahmoud A., additional, Pugh, Trevor, additional, Tyers, Mike, additional, Angers, Stephane, additional, Dirks, Peter B., additional, Bader, Gary D., additional, Massirer, Katlin B., additional, Barsyte-Lovejoy, Dalia, additional, Shechter, David, additional, Harding, Rachel J., additional, Arrowsmith, Cheryl H., additional, and Prinos, Panagiotis, additional
- Published
- 2024
- Full Text
- View/download PDF
7. Drugst.One — a plug-and-play solution for online systems medicine and network-based drug repurposing
- Author
-
Barcelona Supercomputing Center, Maier, Andreas, Hartung, Michael, Abovsky, Mark, Adamowicz, Klaudia, Bader, Gary D, Garcia Hernandez, Carlos, Malod Dognin, Noel, Przulj, Natasa, Barcelona Supercomputing Center, Maier, Andreas, Hartung, Michael, Abovsky, Mark, Adamowicz, Klaudia, Bader, Gary D, Garcia Hernandez, Carlos, Malod Dognin, Noel, and Przulj, Natasa
- Abstract
In recent decades, the de v elopment of ne w drugs has become increasingly e xpensiv e and inefficient, and the molecular mechanisms of most pharmaceuticals remain poorly understood. In response, computational systems and network medicine tools ha v e emerged to identify potential drug repurposing candidates. Ho w e v er, these tools often require complex installation and lack intuitive visual network mining capabilities. To tac kle these c hallenges, we introduce Drugst.One, a platform that assists specialized computational medicine tools in becoming user-friendly, web-based utilities for drug repurposing . W ith just three lines of code, Drugst.One turns any systems biology software into an interactive web tool for modeling and analyzing complex protein-drug-disease networks. Demonstrating its broad adapt abilit y, Drugst.One has been successfully integrated with 21 computational systems medicine tools. Available at https://dr ugst.one , Dr ugst.One has significant potential for streamlining the drug disco v ery process, allowing researchers to focus on essential aspects of pharmaceutical treatment research., REPO-TRIAL: this project has received funding from the European Union’s Horizon 2020 research and innovation programme [777111]; this publication reflects only the authors’ view and the European Commission is not responsible for any use that may be made of the information it contains; RePo4EU: this project is funded by the European Union [101057619]; views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or European Health and Digital Executive Agency (HADEA). Neither the European Union nor the granting authority can be held responsible for them; Swiss State Secretariat for Education, Research and Innovation (SERI) [22.00115]; German Federal Ministry of Education and Research (BMBF) within the framework of ‘CLINSPECT-M/-2’ [F031L0214A, 161L0214A, 16LW0243K]; Technical University Munich – Institute for Advanced Study, funded by the German Excellence Initiative; Intramural Research Programs (IRPs) of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) [422216132]; J.B. was partially funded by his VILLUM Young Investigator Grant [13154]; European Research Council (ERC) Consolidator Grant [770827]; Spanish State Research Agency AEI 10.13039/501100011033 [PID2019-105500GB-I00]; I.J. was supported in part by funding from Natural Sciences Research Council [NSERC #203475], Canada Foundation for Innovation [CFI #225404, #30865]; Ontario Research Fund [RDI #34876, RE010-020]; IBM and Ian Lawson van Toch Fund; S.L. has received funding from the European Union’s Horizon 2020 research and innovation programme [965193] for DECIDER. Funding for open access charge: Horizon Europe project Repo4EU., Peer Reviewed, Postprint (published version)
- Published
- 2024
8. Integrated transcriptomics uncovers an enhanced association between the prion protein gene expression and vesicle dynamics signatures in glioblastomas.
- Author
-
Boccacino, Jacqueline Marcia, dos Santos Peixoto, Rafael, Fernandes, Camila Felix de Lima, Cangiano, Giovanni, Sola, Paula Rodrigues, Coelho, Bárbara Paranhos, Prado, Mariana Brandão, Melo-Escobar, Maria Isabel, de Sousa, Breno Pereira, Ayyadhury, Shamini, Bader, Gary D., Shinjo, Sueli Mieko Oba, Marie, Suely Kazue Nagahashi, da Rocha, Edroaldo Lummertz, and Lopes, Marilene Hohmuth
- Subjects
GENE expression ,TRANSCRIPTOMES ,PROTEIN expression ,CELL communication ,PROTEOMICS ,GLIOBLASTOMA multiforme - Abstract
Background: Glioblastoma (GBM) is an aggressive brain tumor that exhibits resistance to current treatment, making the identification of novel therapeutic targets essential. In this context, cellular prion protein (PrP
C ) stands out as a potential candidate for new therapies. Encoded by the PRNP gene, PrPC can present increased expression levels in GBM, impacting cell proliferation, growth, migration, invasion and stemness. Nevertheless, the exact molecular mechanisms through which PRNP/PrPC modulates key aspects of GBM biology remain elusive. Methods: To elucidate the implications of PRNP/PrPC in the biology of this cancer, we analyzed publicly available RNA sequencing (RNA-seq) data of patient-derived GBMs from four independent studies. First, we ranked samples profiled by bulk RNA-seq as PRNPhigh and PRNPlow and compared their transcriptomic landscape. Then, we analyzed PRNP+ and PRNP- GBM cells profiled by single-cell RNA-seq to further understand the molecular context within which PRNP/PrPC might function in this tumor. We explored an additional proteomics dataset, applying similar comparative approaches, to corroborate our findings. Results: Functional profiling revealed that vesicular dynamics signatures are strongly correlated with PRNP/PrPC levels in GBM. We found a panel of 73 genes, enriched in vesicle-related pathways, whose expression levels are increased in PRNPhigh /PRNP+ cells across all RNA-seq datasets. Vesicle-associated genes, ANXA1, RAB31, DSTN and SYPL1, were found to be upregulated in vitro in an in-house collection of patient-derived GBM. Moreover, proteome analysis of patient-derived samples reinforces the findings of enhanced vesicle biogenesis, processing and trafficking in PRNPhigh /PRNP+ GBM cells. Conclusions: Together, our findings shed light on a novel role for PrPC as a potential modulator of vesicle biology in GBM, which is pivotal for intercellular communication and cancer maintenance. We also introduce GBMdiscovery, a novel user-friendly tool that allows the investigation of specific genes in GBM biology. [ABSTRACT FROM AUTHOR]- Published
- 2024
- Full Text
- View/download PDF
9. Interpretable single-cell factor decomposition using sciRED.
- Author
-
Pouyabahar D, Andrews T, and Bader GD
- Abstract
Single-cell RNA sequencing (scRNA-seq) maps gene expression heterogeneity within a tissue. However, identifying biological signals in this data is challenging due to confounding technical factors, sparsity, and high dimensionality. Data factorization methods address this by separating and identifying signals in the data, such as gene expression programs, but the resulting factors must be manually interpreted. We developed Single-Cell Interpretable Residual Decomposition (sciRED) to improve the interpretation of scRNA-seq factor analysis. sciRED removes known confounding effects, uses rotations to improve factor interpretability, maps factors to known covariates, identifies unexplained factors that may capture hidden biological phenomena and determines the genes and biological processes represented by the resulting factors. We apply sciRED to multiple scRNA-seq datasets and identify sex-specific variation in a kidney map, discern strong and weak immune stimulation signals in a PBMC dataset, reduce ambient RNA contamination in a rat liver atlas to help identify strain variation, and reveal rare cell type signatures and anatomical zonation gene programs in a healthy human liver map. These demonstrate that sciRED is useful in characterizing diverse biological signals within scRNA-seq data.
- Published
- 2024
- Full Text
- View/download PDF
10. Metformin reduces the clonal fitness of Dnmt3a R878H hematopoietic stem and progenitor cells by reversing their aberrant metabolic and epigenetic state.
- Author
-
Hosseini M, Voisin V, Chegini A, Varesi A, Cathelin S, Ayyathan DM, Liu ACH, Yang Y, Wang V, Maher A, Grignano E, Reisz JA, D'Alessandro A, Young K, Wu Y, Fiumara M, Ferrari S, Naldini L, Gaiti F, Pai S, Schimmer AD, Bader GD, Dick JE, Xie SZ, Trowbridge JJ, and Chan SM
- Abstract
Clonal hematopoiesis (CH) arises when a hematopoietic stem cell (HSC) acquires a mutation that confers a competitive advantage over wild-type (WT) HSCs, resulting in its clonal expansion. Individuals with CH are at an increased risk of developing hematologic neoplasms and a range of age-related inflammatory illnesses
1-3 . Therapeutic interventions that suppress the expansion of mutant HSCs have the potential to prevent these CH-related illnesses; however, such interventions have not yet been identified. The most common CH driver mutations are in the DNA methyltransferase 3 alpha ( DNMT3A ) gene with arginine 882 (R882) being a mutation hotspot. Here we show that murine hematopoietic stem and progenitor cells (HSPCs) carrying the Dnmt3aR878H/+ mutation, which is equivalent to human DNMT3AR882H/+ , have increased mitochondrial respiration compared with WT cells and are dependent on this metabolic reprogramming for their competitive advantage. Importantly, treatment with metformin, an oral anti-diabetic drug with inhibitory activity against complex I in the electron transport chain (ETC), reduced the fitness of Dnmt3aR878H/+ HSCs. Through a multi-omics approach, we discovered that metformin acts by enhancing the methylation potential in Dnmt3aR878H/+ HSPCs and reversing their aberrant DNA CpG methylation and histone H3K27 trimethylation (H3K27me3) profiles. Metformin also reduced the fitness of human DNMT3AR882H HSPCs generated by prime editing. Our findings provide preclinical rationale for investigating metformin as a preventive intervention against illnesses associated with DNMT3AR882 mutation-driven CH in humans., Competing Interests: Conflicts of Interest S.M.C. has received research funding from the Centre for Oncology and Immunology in Hong Kong, Celgene/BMS, AbbVie Pharmaceuticals, Agios Pharmaceuticals, and Servier Laboratories. F.G. serves as a consultant for S2 Genomics Inc. A.D.S. has received research funding from Takeda Pharmaceuticals, BMS and Medivir AB, and consulting fees/honorarium from Takeda, Novartis, Jazz, and Otsuka Pharmaceuticals. A.D.S. is named on a patent application for the use of DNT cells to treat AML. A.D.S. is a member of the Medical and Scientific Advisory Board of the Leukemia and Lymphoma Society of Canada. A.D.S. holds the Ronald N. Buick Chair in Oncology Research. J.E.D. has received research funding from Celgene/BMS, and has patents licensed to Trillium Therapeutics/Pfizer.- Published
- 2024
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.